TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High Dose Versus Standard Dose Proton Pump Inhibitor in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Hemostasis: A Prospective Randomized Comparative Study
Brief Summary: The study was designed to evaluate the efficacy an adjuvant use of standard dose or high dose of proton pump inhibitor after combined endoscopic hemostasis therapy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: High dose pantoprazole infusion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard dose pantoprazole infusion | Intervention Type: DRUG; Name: High dose pantoprazole infusion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Standard dose pantoprazole infusion; Assigned to Arm(s): 2
B: Arm Label: lansoprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: lansoprazole | Arm Label: esomeprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole | Intervention Type: DRUG; Name: lansoprazole; Assigned to Arm(s): lansoprazole | Intervention Type: DRUG; Name: esomeprazole; Assigned to Arm(s): esomeprazole
C: Arm Label: Double oral dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) | Arm Label: Regular oral dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) | Intervention Type: DRUG; Name: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden); Assigned to Arm(s): Control group, Double oral dose, Regular oral dose
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omeprazole | Intervention Type: DRUG; Name: Omeprazole; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Neuromuscular Electrostimulation (NMES) for Treatment or Prevention of ICU-Associated Weakness
Brief Summary: The purpose of this study is to investigate whether neuromuscular electrostimulation (NMES) will decrease ICU-associated weakness. The investigators believe that 60 minutes of daily NMES will improve strength and function in those who have had extended ICU stays, as well as decrease critical illness myopathy as an etiology of weakness in the critically ill.


Options:
A: Arm Label: Functional electrical stimulation; Type: EXPERIMENTAL; Interventions: Procedure: Functional electrical stimulation | Arm Label: Medium-frequency alternating current; Type: EXPERIMENTAL; Interventions: Procedure: Medium-frequency alternating current | Arm Label: Burst-modulated alternating current; Type: EXPERIMENTAL; Interventions: Procedure: Burst-modulated alternating current | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo | Intervention Type: PROCEDURE; Name: Medium-frequency alternating current; Assigned to Arm(s): Medium-frequency alternating current | Intervention Type: PROCEDURE; Name: Burst-modulated alternating current; Assigned to Arm(s): Burst-modulated alternating current | Intervention Type: PROCEDURE; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: PROCEDURE; Name: Functional electrical stimulation; Assigned to Arm(s): Functional electrical stimulation
B: Arm Label: EMS group; Type: EXPERIMENTAL; Interventions: Procedure: EMS | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: EMS; Assigned to Arm(s): EMS group
C: Arm Label: NMES; Type: EXPERIMENTAL; Interventions: Device: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA) | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA); Assigned to Arm(s): NMES | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham
D: Arm Label: NMES group; Type: EXPERIMENTAL; Interventions: Other: Neuromuscular electrical stimulation, Other: Endurance training, Other: Quadriceps strength training | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Other: Endurance training, Other: Quadriceps strength training | Intervention Type: OTHER; Name: Neuromuscular electrical stimulation; Assigned to Arm(s): NMES group | Intervention Type: OTHER; Name: Endurance training; Assigned to Arm(s): Control group, NMES group | Intervention Type: OTHER; Name: Quadriceps strength training; Assigned to Arm(s): Control group, NMES group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Neuromuscular Electrostimulation (NMES) for Treatment or Prevention of ICU-Associated Weakness
Brief Summary: The purpose of this study is to investigate whether neuromuscular electrostimulation (NMES) will decrease ICU-associated weakness. The investigators believe that 60 minutes of daily NMES will improve strength and function in those who have had extended ICU stays, as well as decrease critical illness myopathy as an etiology of weakness in the critically ill.


Options:
A: Arm Label: EMS group; Type: EXPERIMENTAL; Interventions: Procedure: EMS | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: EMS; Assigned to Arm(s): EMS group
B: Arm Label: Early PT OT; Type: EXPERIMENTAL; Interventions: Procedure: early PT OT | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: early PT OT; Assigned to Arm(s): Early PT OT
C: Arm Label: NMES; Type: EXPERIMENTAL; Interventions: Device: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA) | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA); Assigned to Arm(s): NMES | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Traditional management | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Fast track patient management | Intervention Type: PROCEDURE; Name: Fast track patient management; Assigned to Arm(s): B | Intervention Type: PROCEDURE; Name: Traditional management; Assigned to Arm(s): A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Neuromuscular Electrostimulation (NMES) for Treatment or Prevention of ICU-Associated Weakness
Brief Summary: The purpose of this study is to investigate whether neuromuscular electrostimulation (NMES) will decrease ICU-associated weakness. The investigators believe that 60 minutes of daily NMES will improve strength and function in those who have had extended ICU stays, as well as decrease critical illness myopathy as an etiology of weakness in the critically ill.


Options:
A: Intervention Type: PROCEDURE; Name: inspiratory muscle strength training; Assigned to Arm(s): N/A
B: Arm Label: EMS group; Type: EXPERIMENTAL; Interventions: Procedure: EMS | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: EMS; Assigned to Arm(s): EMS group
C: Arm Label: NMES; Type: EXPERIMENTAL; Interventions: Device: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA) | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA); Assigned to Arm(s): NMES | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham
D: Intervention Type: DRUG; Name: intensive insulin therapy to maintain normoglycemia; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multifaceted Depression Diabetes Program for Hispanics
Brief Summary: This study will evaluate the effectiveness of culturally adapted depression treatment for reducing depressive symptoms and improving adherence to diabetes self-care regimens in Hispanics with depression and diabetes.


Options:
A: Intervention Type: BEHAVIORAL; Name: Program to Encourage Active, Rewarding Lives (PEARL); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Depression care management by secure messaging | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Depression care management by secure messaging; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative depression care management | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Collaborative depression care management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Enhanced usual care; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Treatment of depression; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Suicide prevention intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Suicide prevention treatment; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multifaceted Depression Diabetes Program for Hispanics
Brief Summary: This study will evaluate the effectiveness of culturally adapted depression treatment for reducing depressive symptoms and improving adherence to diabetes self-care regimens in Hispanics with depression and diabetes.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative depression care management | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Collaborative depression care management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Enhanced usual care; Assigned to Arm(s): 2
B: Arm Label: CALM Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral therapy, Drug: Psychotropic medication optimization | Arm Label: Treatment as Usual (TAU); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral therapy; Assigned to Arm(s): CALM Intervention | Intervention Type: DRUG; Name: Psychotropic medication optimization; Assigned to Arm(s): CALM Intervention | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual (TAU)
C: Arm Label: access to intermediate care clinics; Type: EXPERIMENTAL; Interventions: Other: intermediate care clinics (ICCs) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: intermediate care clinics (ICCs); Assigned to Arm(s): access to intermediate care clinics
D: Arm Label: ICC; Type: EXPERIMENTAL; Interventions: Other: Integrated collaborative care | Arm Label: E&R; Type: ACTIVE_COMPARATOR; Interventions: Other: Education and Resources | Intervention Type: OTHER; Name: Integrated collaborative care; Assigned to Arm(s): ICC | Intervention Type: OTHER; Name: Education and Resources; Assigned to Arm(s): E&R

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multifaceted Depression Diabetes Program for Hispanics
Brief Summary: This study will evaluate the effectiveness of culturally adapted depression treatment for reducing depressive symptoms and improving adherence to diabetes self-care regimens in Hispanics with depression and diabetes.


Options:
A: Arm Label: IDEAL intervention; Type: EXPERIMENTAL; Interventions: Other: IDEAL intervention | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: IDEAL intervention; Assigned to Arm(s): IDEAL intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative depression care management | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Collaborative depression care management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Enhanced usual care; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Bipolar Disorder Program | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual (psychiatric) Care | Intervention Type: BEHAVIORAL; Name: Bipolar Disorder Program; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual (psychiatric) Care; Assigned to Arm(s): 2
D: Arm Label: Virtual Learning Collaborative; Type: EXPERIMENTAL; Interventions: Other: Virtual Learning Collaborative | Arm Label: Technical Assistance; Type: ACTIVE_COMPARATOR; Interventions: Other: Technical Assistance | Intervention Type: OTHER; Name: Virtual Learning Collaborative; Assigned to Arm(s): Virtual Learning Collaborative | Intervention Type: OTHER; Name: Technical Assistance; Assigned to Arm(s): Technical Assistance

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Outcomes of Triaged Family Care in Advanced Cancer
Brief Summary: The purpose of this study is to assess the quality of life of patients with advanced cancer and their family caregivers and to evaluate two doses of a family-based program of care versus control.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: clino-san vaginal lubricant | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: clino-san vaginal lubricant | Intervention Type: DRUG; Name: clino-san vaginal lubricant; Assigned to Arm(s): 1, 2
B: Arm Label: Brief; Type: EXPERIMENTAL; Interventions: Behavioral: Brief FOCUS Program | Arm Label: Extensive; Type: EXPERIMENTAL; Interventions: Behavioral: Extensive FOCUS Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief FOCUS Program; Assigned to Arm(s): Brief | Intervention Type: BEHAVIORAL; Name: Extensive FOCUS Program; Assigned to Arm(s): Extensive
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone | Intervention Type: DRUG; Name: Testosterone; Assigned to Arm(s): 1, 2, 3, 4, 5
D: Arm Label: Control Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone counseling, Behavioral: Telephone interview | Arm Label: Usual Care Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone counseling, Behavioral: Telephone interview | Intervention Type: BEHAVIORAL; Name: Telephone counseling; Assigned to Arm(s): Control Arm, Usual Care Arm | Intervention Type: BEHAVIORAL; Name: Telephone interview; Assigned to Arm(s): Control Arm, Usual Care Arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Outcomes of Triaged Family Care in Advanced Cancer
Brief Summary: The purpose of this study is to assess the quality of life of patients with advanced cancer and their family caregivers and to evaluate two doses of a family-based program of care versus control.


Options:
A: Arm Label: Psycho-educational support group therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Psycho-educational support group therapy | Intervention Type: BEHAVIORAL; Name: Psycho-educational support group therapy; Assigned to Arm(s): Psycho-educational support group therapy
B: Arm Label: Brief; Type: EXPERIMENTAL; Interventions: Behavioral: Brief FOCUS Program | Arm Label: Extensive; Type: EXPERIMENTAL; Interventions: Behavioral: Extensive FOCUS Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief FOCUS Program; Assigned to Arm(s): Brief | Intervention Type: BEHAVIORAL; Name: Extensive FOCUS Program; Assigned to Arm(s): Extensive
C: Intervention Type: DEVICE; Name: Comprehensive Health Enhancement Support System; Assigned to Arm(s): N/A
D: Arm Label: Psychological Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychological intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychological intervention; Assigned to Arm(s): Psychological Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Attenuation of Second Generation Antipsychotic Induced Weight Gain in Adolescents and Adults Using Betahistine: A Double-Blind, Placebo-Controlled Trial
Brief Summary: The study attempts to evaluate a histamine analog long used for the treatment of Meniere's disease, betahistine, that shows promise in reversing the antihistaminergic effects thought to be involved in antipsychotic induced weight gain.

Hypothesis to be tested:

A. Patients who have gained a developmentally inappropriate amount of weight on antipsychotics (AP) will see their weight and BMI decrease with betahistine augmentation as compared to placebo augmentation.

B. Betahistine augmentation in AP treated patients will increase levels of satiety in a standardized meal situation and decrease caloric intake as compared to placebo augmentation.

C. Metabolic effects of betahistine augmentation in AP treated patients will be reflected in differences in waist circumference, hip circumference and waist hip ratios D. Betahistine augmentation in this population will lead to decrease in fasting glucose-lipid lab values related to the development of metabolic syndrome as compared to placebo augmentation


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Betahistine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Betahistine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): 2
B: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
C: Arm Label: metformin 500 mg/d; clozapine 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin 500 mg, Drug: clozapine 100 mg | Arm Label: metformin 1000 mg/d; clozapine 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin 500 mg, Drug: clozapine 100 mg | Arm Label: placebo; clozapine 100 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: metformin 500 mg, Drug: clozapine 100 mg | Intervention Type: DRUG; Name: metformin 500 mg; Assigned to Arm(s): metformin 1000 mg/d; clozapine 100 mg, metformin 500 mg/d; clozapine 100 mg, placebo; clozapine 100 mg | Intervention Type: DRUG; Name: clozapine 100 mg; Assigned to Arm(s): metformin 1000 mg/d; clozapine 100 mg, metformin 500 mg/d; clozapine 100 mg, placebo; clozapine 100 mg
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: exenatide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Exenatide | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): exenatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infant Study of Inhaled Saline in Cystic Fibrosis
Brief Summary: The purpose of this study is to assess whether 7% hypertonic saline (HS) is an effective and safe therapy in infants and young children with CF.


Options:
A: Arm Label: Active treatment group; Type: EXPERIMENTAL; Interventions: Drug: 7% Hypertonic Saline (HS) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9% Isotonic Saline (IS) | Intervention Type: DRUG; Name: 7% Hypertonic Saline (HS); Assigned to Arm(s): Active treatment group | Intervention Type: DRUG; Name: 0.9% Isotonic Saline (IS); Assigned to Arm(s): Control group
B: Arm Label: Active Treatment Group; Type: EXPERIMENTAL; Interventions: Drug: 7% Hypertonic Saline (HS) | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9% Isotonic Saline (IS) | Intervention Type: DRUG; Name: 7% Hypertonic Saline (HS); Assigned to Arm(s): Active Treatment Group | Intervention Type: DRUG; Name: 0.9% Isotonic Saline (IS); Assigned to Arm(s): Control Group
C: Arm Label: Active Treatment Group; Type: EXPERIMENTAL; Interventions: Drug: Active Treatment Group 7% Hypertonic Saline | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Control Group 0.9% Isotonic Saline | Intervention Type: DRUG; Name: Active Treatment Group 7% Hypertonic Saline; Assigned to Arm(s): Active Treatment Group | Intervention Type: DRUG; Name: Control Group 0.9% Isotonic Saline; Assigned to Arm(s): Control Group
D: Arm Label: Group A; Type: N/A; Interventions: Behavioral: Qualitative Interview | Arm Label: Group B; Type: N/A; Interventions: Behavioral: Qualitative Interview | Arm Label: Group C; Type: N/A; Interventions: Behavioral: Qualitative Interview | Arm Label: Group D; Type: N/A; Interventions: Behavioral: Qualitative Interview | Arm Label: Group E; Type: N/A; Interventions: Behavioral: Qualitative Interview | Intervention Type: BEHAVIORAL; Name: Qualitative Interview; Assigned to Arm(s): Group A, Group B, Group C, Group D, Group E

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infant Study of Inhaled Saline in Cystic Fibrosis
Brief Summary: The purpose of this study is to assess whether 7% hypertonic saline (HS) is an effective and safe therapy in infants and young children with CF.


Options:
A: Arm Label: Active treatment group; Type: EXPERIMENTAL; Interventions: Drug: 7% Hypertonic Saline (HS) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9% Isotonic Saline (IS) | Intervention Type: DRUG; Name: 7% Hypertonic Saline (HS); Assigned to Arm(s): Active treatment group | Intervention Type: DRUG; Name: 0.9% Isotonic Saline (IS); Assigned to Arm(s): Control group
B: Arm Label: ACTs after HTS inhalation:; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Arm Label: ACTs during HTS inhalation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Intervention Type: PROCEDURE; Name: Airways clearance and Hypertonic saline inhalation; Assigned to Arm(s): ACTs after HTS inhalation:, ACTs during HTS inhalation
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 2
D: Arm Label: 7% saline; Type: EXPERIMENTAL; Interventions: Drug: 7% saline | Arm Label: 0.12% saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.12% saline | Intervention Type: DRUG; Name: 0.12% saline; Assigned to Arm(s): 0.12% saline | Intervention Type: DRUG; Name: 7% saline; Assigned to Arm(s): 7% saline

Answer: A